Small-molecule albumin ligand modification to enhance the anti-diabetic ability of GLP-1 derivatives
Authors:
Open Access
- 21 February 2022
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 148, 112722
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Hunan Province (2021JJ40335)
- Science and Technology Program of Hunan Province (2018TP1017)
- Science and Technology Program of Hunan Province (2020RC2051)
- National Natural Science Foundation of China (21877036)
This publication has 43 references indexed in Scilit:
- Treatment with pravastatin attenuates progression of chronic pancreatitis in ratLaboratory Investigation, 2011
- The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeuticsJournal of Controlled Release, 2010
- Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogsJournal of Controlled Release, 2010
- GLP-1 protects β-cells against apoptosis by enhancing the activity of an IGF-2/IGF1-receptor autocrine loopIslets, 2009
- Preparation and Structural, Biochemical, and Pharmaceutical Characterizations of Bile Acid-Modified Long-Acting Exendin-4 DerivativesJournal of Medicinal Chemistry, 2009
- Chemoenzymatic Synthesis of Glycosylated Glucagon-like Peptide 1: Effect of Glycosylation on Proteolytic Resistance and in Vivo Blood Glucose-Lowering ActivityJournal of the American Chemical Society, 2009
- Glucagon-like Peptide-1 Activation of TCF7L2-dependent Wnt Signaling Enhances Pancreatic Beta Cell ProliferationJournal of Biological Chemistry, 2008
- GLP-1 Receptor Agonists and DPP-4 Inhibitors in the Treatment of Type 2 DiabetesHormone and Metabolic Research, 2004
- Global and societal implications of the diabetes epidemicNature, 2001
- Kinetics of Bilirubin Transfer between Serum Albumin and Membrane VesiclesJournal of Biological Chemistry, 1995